Renaissance Technologies LLC Decreases Position in Genelux Co. (NASDAQ:GNLX)

Renaissance Technologies LLC cut its position in shares of Genelux Co. (NASDAQ:GNLX - Free Report) by 88.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 14,551 shares of the company's stock after selling 107,986 shares during the quarter. Renaissance Technologies LLC's holdings in Genelux were worth $34,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of GNLX. Virtu Financial LLC purchased a new position in Genelux during the fourth quarter worth $25,000. Apollon Wealth Management LLC increased its position in Genelux by 20.4% during the fourth quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company's stock worth $40,000 after buying an additional 2,857 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Genelux during the fourth quarter worth $41,000. D.A. Davidson & CO. purchased a new stake in shares of Genelux in the fourth quarter valued at $51,000. Finally, LifeSteps Financial Inc. grew its position in shares of Genelux by 11.1% in the fourth quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company's stock valued at $205,000 after purchasing an additional 8,715 shares during the period. 37.33% of the stock is owned by institutional investors and hedge funds.

Genelux Price Performance

GNLX stock traded down $0.18 during trading on Monday, reaching $2.78. 494,669 shares of the stock traded hands, compared to its average volume of 212,771. The business's 50 day moving average price is $2.96 and its 200-day moving average price is $3.12. Genelux Co. has a 52-week low of $1.60 and a 52-week high of $5.89. The firm has a market capitalization of $104.90 million, a PE ratio of -2.93 and a beta of -0.33.

Genelux (NASDAQ:GNLX - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.03. On average, equities research analysts predict that Genelux Co. will post -0.88 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. HC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of Genelux in a research report on Monday, March 31st. Benchmark lowered their price target on Genelux from $25.00 to $23.00 and set a "speculative buy" rating for the company in a research report on Thursday. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $17.75.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.